Nima Farzan - 04 Jun 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
04 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 16:15:17 UTC
Previous filing
03 Jun 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Nima Farzan filed Form 4 for Keros Therapeutics, Inc. (KROS) on 06 Jun 2025."

Quick Takeaways

  • This page summarizes Nima Farzan's Form 4 filing for Keros Therapeutics, Inc. (KROS).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 06 Jun 2025, 16:15.

What Changed

  • Previous filing in this sequence was filed on 03 Jun 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farzan Nima Director C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Keith Regnante, Attorney-in-Fact 06 Jun 2025 0001808296

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Award $0 +5,250 $0.000000 5,250 04 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (right to buy) Award $0 +10,500 $0.000000 10,500 04 Jun 2025 Common Stock 10,500 $14.82 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
F2 The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Sponsored